Chronic lymphocytic leukemia (CLL) is a blood cancer caused by the excessive accumulation of abnormal B lymphocytes in the blood, bone marrow, and lymph nodes. Over the past 10 years, the treatment landscape of CLL has evolved, with most traditional chemotherapy options being replaced with more targeted treatment approaches. One of the most significant treatment breakthroughs has been the use of Bruton tyrosine kinase (BTK) Inhibitors.
These drugs inhibit the action of a vital protein involved in the survival of leukemia cells. Brukinsa (Zanubrutinib) and Jaypirca (Pirtobrutinib) are two of the most studied BTK inhibitors. Although both medicines are designed to inhibit the same protein, they are formulated differently and are intended for use at different lines of treatment for CLL.
Why BTK Inhibitors Matter in CLL
One of the most important enzymes in the immune system is called BTK. It is crucial to the B-cell receptor signalling pathway, which is important for the growth of B cells and their responses to other cells in the immune system.
Unfortunately, in the case of CLL, that same pathway helps malignant B cells thrive and expand. Inevitably, BTK inhibitors work to weaken the signalling that helps leukemia cells live. Therapies that target these pathways are able to help control CLL and slow the progression of the disease.
Because of this targeted mechanism, BTK inhibitors are a new and crucial line of therapy and are being integrated into the treatment paradigm of CLL.
Brukinsa and Its Role in CLL
Brukinsa is the brand name for Zanubrutinib. It is a covalent BTK inhibitor with an ability to bind BTK enzymes tightly. This drug stops BTK from being active, which stops the survival signals used by the leukemia cells.
The SEQUOIA and ALPINE trials are examples of some of the clinical trials of Zanubrutinib focused on patients with newly diagnosed and also patients with relapsed CLL.
These studies have demonstrated strong disease control and improved progression-free survival compared with some previous lines of treatment. Consequently, Zanubrutinib has come to symbolize the growing importance of BTK inhibitors in CLL.
Jaypirca and the Next Generation of BTK Inhibitors
Jaypirca, the brand name for Pirtobrutinib. It is a newer type of BTK inhibitor with a different mechanism of action. Instead of permanently binding to BTK like prior medications, Pirtobrutinib binds reversibly.
This mechanism enables the drug to continue working even if there are mutations that covalent inhibitors are not able to target. Jaypirca was approved for use in relapsed or refractory CLL patients that have had prior treatment with a covalent BTK inhibitor.
The BRUIN research program clinical trials showed promising response rates in patients whose disease progressed after prior therapies.
Comparing Their Roles in Treatment
When discussing jaypirca vs brukinsa, the discussions usually focus on how the individual therapies integrate into the overall treatment.
- Brukinsa has a wealth of clinical data supporting its use in both untreated and treated CLL.
- Jaypirca on the other hand is utilized in instances where a patient has received a covalent BTK inhibitor previously.
Since the two drugs were studied in different clinical scenarios, direct treatment comparisons should be made with caution. Rather, they are most commonly considered as treatment options for different phases of the disease.
Safety and Clinical Considerations
Like other targeted cancer therapies, BTK inhibitors can have side effects that can vary from patient to patient. Doctors typically consider a variety of medical factors when selecting a treatment for a patient.
- Common side effects: Patients may experience fatigue, infection, bruising, and lower blood cell counts.
- Patient health status: Patient’s overall health and other comorbidities may affect treatment.
- Previous treatments: Treatments received in the past are considered in the selection of treatment.
- Genetic risk markers: Some mutations can impact the effectiveness of the treatment.
- Monitoring needs: Regular tests and check-ups are needed to track safety and effectiveness.
Ongoing Research in BTK Inhibitor Therapy
The research and application of BTK inhibitors is ever evolving. Clinical trials focus on overcoming treatment resistance by evaluating combinations of targeted therapies to improve long-term outcomes. The refinement of BTK inhibitors will improve the methodologies on their application throughout the continuum of care for chronic lymphocytic leukemia.
